AngioDynamics Current Deferred Revenue from 2010 to 2025

ANGO Stock  USD 9.92  0.05  0.51%   
AngioDynamics Current Deferred Revenue yearly trend continues to be very stable with very little volatility. Current Deferred Revenue is likely to grow to about -16.1 M this year. Current Deferred Revenue is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. View All Fundamentals
 
Current Deferred Revenue  
First Reported
2003-05-31
Previous Quarter
-1.7 M
Current Value
34.1 M
Quarterly Volatility
11.8 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check AngioDynamics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AngioDynamics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 18.5 M, Interest Expense of 1.7 M or Total Revenue of 246.7 M, as well as many indicators such as Price To Sales Ratio of 0.91, Dividend Yield of 0.0 or PTB Ratio of 1.17. AngioDynamics financial statements analysis is a perfect complement when working with AngioDynamics Valuation or Volatility modules.
  
Check out the analysis of AngioDynamics Correlation against competitors.
To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.

Latest AngioDynamics' Current Deferred Revenue Growth Pattern

Below is the plot of the Current Deferred Revenue of AngioDynamics over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. AngioDynamics' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AngioDynamics' overall financial position and show how it may be relating to other accounts over time.
Current Deferred Revenue10 Years Trend
Slightly volatile
   Current Deferred Revenue   
       Timeline  

AngioDynamics Current Deferred Revenue Regression Statistics

Arithmetic Mean5,902,279
Coefficient Of Variation289.90
Mean Deviation13,919,631
Median3,138,000
Standard Deviation17,110,883
Sample Variance292.8T
Range49.3M
R-Value(0.35)
Mean Square Error275.7T
R-Squared0.12
Significance0.19
Slope(1,250,625)
Total Sum of Squares4391.7T

AngioDynamics Current Deferred Revenue History

2025-16.1 M
2024-17 M
2022-14.8 M
202116 M
2020-2.4 M
201829.5 M
201732.3 M

About AngioDynamics Financial Statements

AngioDynamics investors utilize fundamental indicators, such as Current Deferred Revenue, to predict how AngioDynamics Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-17 M-16.1 M
When determining whether AngioDynamics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AngioDynamics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Angiodynamics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Angiodynamics Stock:
Check out the analysis of AngioDynamics Correlation against competitors.
To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AngioDynamics. If investors know AngioDynamics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AngioDynamics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.59)
Revenue Per Share
7.064
Quarterly Revenue Growth
(0.08)
Return On Assets
(0.06)
Return On Equity
(0.76)
The market value of AngioDynamics is measured differently than its book value, which is the value of AngioDynamics that is recorded on the company's balance sheet. Investors also form their own opinion of AngioDynamics' value that differs from its market value or its book value, called intrinsic value, which is AngioDynamics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AngioDynamics' market value can be influenced by many factors that don't directly affect AngioDynamics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AngioDynamics' value and its price as these two are different measures arrived at by different means. Investors typically determine if AngioDynamics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AngioDynamics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.